Table 2.
Toxicities*
| Toxicity | Worst Grade* | No. experiencing as acute toxicity† (of 34 patients enrolled) |
No. experiencing as late toxicity‡ (of 34 patients enrolled) |
|---|---|---|---|
| Pain | 1 | 6 | 3 |
| 2 | 0 | 1 | |
| Fatigue | 1 | 17 | 7 |
| Burn | 1 | 3 | 0 |
| Dry skin | 1 | 10 | 5 |
| 2 | 2 | 0 | |
| Hyperpigmentation | 1 | 19 | 6 |
| 2 | 1 | 0 | |
| Hypopigmentation | 1 | 1 | 2 |
| Induration/fibrosis | 1 | 11 | 19 |
| 2 | 1 | 3 | |
| Pruritus | 1 | 2 | 0 |
| Rash | 1 | 7 | 0 |
| Nipple/areolar defect | 1 | 10 | 11 |
| 2 | 3 | 10 | |
| 3 | 0 | 1 | |
| Volume loss/hypoplasia | 1 | 14 | 14 |
| 2 | 3 | 12 | |
| 3 | 0 | 1 | |
| Edema | 1 | 1 | 0 |
| Fibrosis of deep connective tissue | 1 | 2 | 2 |
| Anorexia and nausea | 1 | 1 | 0 |
| Telangiectasia | 1 | 0 | 5 |
| 2 | 0 | 1 | |
| 3 | 0 | 1 | |
| Atrophy (skin) | 1 | 0 | 1 |
| Atrophy (subcutaneous fat) | 2 | 0 | 1 |
| Wound complication | 1 | 0 | 1 |
| Striae | 1 | 0 | 1 |
| Dyspnea | 1 | 0 | 1 |
*
Toxicities scored on the National Cancer Institute’s form for Common Toxicity Criteria for Adverse Events (CTCAE), version 3.0.
†
Acute toxicities are defined as those noted on the CTCAE forms completed while the patient was on treatment, or at the 1-week or 1-month follow-up visits.
‡
Late toxicities are defined as those noted on the CTCAE forms completed at the 6-month or subsequent follow-up visits. One patient developing Class I congestive heart failure deemed secondary to trastuzumab use developed Grade 1 dyspnea and Grade 1 fatigue (included in the late toxicities above).